Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
GW Pharmaceuticals, in Porton Down, England, has launched Sativex, an oromucosal spray for the treatment of spasticity due to multiple sclerosis, in the U.K. The drug contains two cannabinoid active ingredients—THC (Δ9-tetrahydrocannabinol) and CBD (cannabidiol)—both derived from whole extracts of the Cannabis sativa plant. Bayer Schering Pharma has licensed and will distribute the drug. GW will receive a $15 million milestone payment from Bayer Schering to mark U.K. approval of the drug.
This article has been sent to the following recipient: